Bioneer Corporation (064550.KQ)
KRW 19520.0
(-3.84%)
KRW 19520.0
(-3.84%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 315.48 Billion KRW | 5.61% |
| 2022 | 298.73 Billion KRW | 13.84% |
| 2021 | 262.41 Billion KRW | 37.27% |
| 2020 | 191.16 Billion KRW | 132.85% |
| 2019 | 82.09 Billion KRW | 15.95% |
| 2018 | 70.8 Billion KRW | 20.63% |
| 2017 | 58.69 Billion KRW | -28.25% |
| 2016 | 81.8 Billion KRW | 13.64% |
| 2015 | 71.98 Billion KRW | 6.87% |
| 2014 | 67.35 Billion KRW | -3.68% |
| 2013 | 69.93 Billion KRW | 2.65% |
| 2012 | 68.13 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 326.04 Billion KRW | -0.71% |
| 2024 Q1 | 328.36 Billion KRW | 4.08% |
| 2023 Q3 | 320.11 Billion KRW | 2.11% |
| 2023 Q4 | 315.48 Billion KRW | -1.45% |
| 2023 Q1 | 304.59 Billion KRW | 1.96% |
| 2023 FY | 315.48 Billion KRW | 5.61% |
| 2023 Q2 | 313.51 Billion KRW | 2.93% |
| 2022 Q3 | 279.32 Billion KRW | 3.88% |
| 2022 FY | 298.73 Billion KRW | 13.84% |
| 2022 Q4 | 298.73 Billion KRW | 6.95% |
| 2022 Q2 | 268.89 Billion KRW | -0.07% |
| 2022 Q1 | 269.09 Billion KRW | 2.54% |
| 2021 Q1 | 224.89 Billion KRW | 17.64% |
| 2021 Q4 | 262.41 Billion KRW | 3.56% |
| 2021 FY | 262.41 Billion KRW | 37.27% |
| 2021 Q3 | 253.38 Billion KRW | -1.83% |
| 2021 Q2 | 258.1 Billion KRW | 14.76% |
| 2020 FY | 191.16 Billion KRW | 132.85% |
| 2020 Q2 | 125.17 Billion KRW | 43.96% |
| 2020 Q3 | 166.44 Billion KRW | 32.98% |
| 2020 Q4 | 191.16 Billion KRW | 14.85% |
| 2020 Q1 | 86.94 Billion KRW | 5.91% |
| 2019 Q1 | 69.49 Billion KRW | -1.86% |
| 2019 Q2 | 69.24 Billion KRW | -0.36% |
| 2019 Q3 | 68.17 Billion KRW | -1.55% |
| 2019 FY | 82.09 Billion KRW | 15.95% |
| 2019 Q4 | 82.09 Billion KRW | 20.43% |
| 2018 Q1 | 55.47 Billion KRW | -5.49% |
| 2018 FY | 70.8 Billion KRW | 20.63% |
| 2018 Q4 | 70.8 Billion KRW | -6.81% |
| 2018 Q3 | 75.98 Billion KRW | 5.21% |
| 2018 Q2 | 72.21 Billion KRW | 30.18% |
| 2017 FY | 58.69 Billion KRW | -28.25% |
| 2017 Q4 | 58.69 Billion KRW | -15.55% |
| 2017 Q3 | 69.5 Billion KRW | -6.36% |
| 2017 Q2 | 74.22 Billion KRW | 18.74% |
| 2017 Q1 | 62.51 Billion KRW | 11.31% |
| 2016 Q2 | 67.14 Billion KRW | -2.38% |
| 2016 FY | 81.8 Billion KRW | 13.64% |
| 2016 Q3 | 62.13 Billion KRW | -7.47% |
| 2016 Q4 | 56.16 Billion KRW | -9.61% |
| 2016 Q1 | 68.78 Billion KRW | -4.45% |
| 2015 Q1 | 65.48 Billion KRW | -2.78% |
| 2015 Q4 | 71.98 Billion KRW | -0.65% |
| 2015 Q3 | 72.45 Billion KRW | 10.41% |
| 2015 Q2 | 65.62 Billion KRW | 0.21% |
| 2015 FY | 71.98 Billion KRW | 6.87% |
| 2014 Q2 | 74.5 Billion KRW | 5.73% |
| 2014 Q3 | 68.04 Billion KRW | -8.68% |
| 2014 Q4 | 67.35 Billion KRW | -1.01% |
| 2014 Q1 | 70.47 Billion KRW | 0.77% |
| 2014 FY | 67.35 Billion KRW | -3.68% |
| 2013 FY | 69.93 Billion KRW | 2.65% |
| 2013 Q4 | 69.93 Billion KRW | -0.9% |
| 2013 Q3 | 70.56 Billion KRW | -4.86% |
| 2013 Q2 | 74.17 Billion KRW | 7.52% |
| 2013 Q1 | 68.98 Billion KRW | 1.25% |
| 2012 FY | 68.13 Billion KRW | 0.0% |
| 2012 Q4 | 68.13 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| HLB Co., Ltd. | 751.72 Billion KRW | 58.031% |
| iNtRON Biotechnology, Inc. | 98.61 Billion KRW | -219.919% |
| BINEX Co., Ltd. | 257.01 Billion KRW | -22.752% |
| Anterogen.Co.,Ltd. | 149.43 Billion KRW | -111.125% |
| MEDIPOST Co., Ltd. | 449.39 Billion KRW | 29.797% |
| CrystalGenomics, Inc. | 243.11 Billion USD | -29.768% |
| Helixmith Co., Ltd | 227.27 Billion KRW | -38.81% |
| Chabiotech Co.,Ltd. | 1725.57 Billion KRW | 81.717% |
| Medy-Tox Inc. | 611.62 Billion KRW | 48.418% |
| Peptron, Inc. | 52.49 Billion KRW | -500.974% |
| Amicogen, Inc. | 467.09 Billion KRW | 32.458% |
| Genexine, Inc. | 376.58 Billion KRW | 16.225% |
| HLB Therapeutics Co.,Ltd. | 200.79 Billion KRW | -57.119% |
| LegoChem Biosciences, Inc. | 189.5 Billion KRW | -66.482% |
| ALTEOGEN Inc. | 256.09 Billion KRW | -23.189% |
| PharmaResearch Co., Ltd. | 535.28 Billion KRW | 41.061% |
| SillaJen, Inc. | 76.71 Billion KRW | -311.246% |
| JETEMA, Co., Ltd. | 252.14 Billion KRW | -25.12% |
| OliX Pharmaceuticals,Inc | 102.82 Billion KRW | -206.819% |
| Genomictree Inc. | 132.84 Billion KRW | -137.487% |
| MedPacto, Inc. | 80.47 Billion KRW | -292.034% |
| D&D Pharmatech | 79.2 Billion KRW | -298.324% |
| EASY BIO,Inc. | 172.04 Billion KRW | -83.379% |
| GI Innovation, Inc. | 81.34 Billion KRW | -287.861% |